• Je něco špatně v tomto záznamu ?

Imipridone enhances vascular relaxation via FOXO1 pathway

KR. McSweeney, LK. Gadanec, T. Qaradakhi, TM. Gammune, P. Kubatka, M. Caprnda, J. Fedotova, J. Radonak, P. Kruzliak, A. Zulli

. 2020 ; 47 (11) : 1816-1823. [pub] 20200803

Jazyk angličtina Země Austrálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004813

Cardiovascular complications are a side effect of cancer therapy, potentially through reduced blood vessel function. ONC201 (TIC10) is currently used in phase 2 clinical trials to treat high-grade gliomas. TIC10 is a phosphatidylinositol 3-kinase (PI3K)/AKT/extracellular signal-regulated kinase (ERK) inhibitor that induces apoptosis via upregulation of TNF-related apoptosis-inducing ligand, which via stimulation of FOXO and death receptor could increase eNOS upregulation. This has the potential to improve vascular function through increased NO bioavailability. Our aim was to investigate the role of TIC10 on vascular function to determine if it would affect the risk of CVD. Excised abdominal aorta from White New Zealand male rabbits were cut into rings. Vessels were incubated with TIC10 and AS1842856 (FOXO1 inhibitor) followed by cumulative doses of acetylcholine (Ach) to assess vessel function. Vessels were then processed for immunohistochemistry. Incubation of blood vessels with TIC10 resulted in enhanced vasodilatory capacity. Combination treatment with the FOXO1 inhibitor and TIC10 resulted in reduced vascular function compared to control. Immunohistochemical analysis indicated a 3-fold increase in death receptor 5 (DR5) expression in the TIC10-treated blood vessels but the addition of the FOXO1 inhibitor downregulated DR5 expression. The expression of DR4 receptor was not significantly increased in the presence of TIC10; however, addition of the FOXO1 inhibitor downregulated expression. TIC10 has the capacity to improve the function of healthy vessels when stimulated with the vasodilator Ach. This highlights its therapeutic potential not only in cancer treatment without cardiovascular side effects, but also as a possible drug to treat established CVD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004813
003      
CZ-PrNML
005      
20220127144941.0
007      
ta
008      
220113s2020 at f 000 0|eng||
009      
AR
024    7_
$a 10.1111/1440-1681.13377 $2 doi
035    __
$a (PubMed)32652671
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a McSweeney, Kristen R $u Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia
245    10
$a Imipridone enhances vascular relaxation via FOXO1 pathway / $c KR. McSweeney, LK. Gadanec, T. Qaradakhi, TM. Gammune, P. Kubatka, M. Caprnda, J. Fedotova, J. Radonak, P. Kruzliak, A. Zulli
520    9_
$a Cardiovascular complications are a side effect of cancer therapy, potentially through reduced blood vessel function. ONC201 (TIC10) is currently used in phase 2 clinical trials to treat high-grade gliomas. TIC10 is a phosphatidylinositol 3-kinase (PI3K)/AKT/extracellular signal-regulated kinase (ERK) inhibitor that induces apoptosis via upregulation of TNF-related apoptosis-inducing ligand, which via stimulation of FOXO and death receptor could increase eNOS upregulation. This has the potential to improve vascular function through increased NO bioavailability. Our aim was to investigate the role of TIC10 on vascular function to determine if it would affect the risk of CVD. Excised abdominal aorta from White New Zealand male rabbits were cut into rings. Vessels were incubated with TIC10 and AS1842856 (FOXO1 inhibitor) followed by cumulative doses of acetylcholine (Ach) to assess vessel function. Vessels were then processed for immunohistochemistry. Incubation of blood vessels with TIC10 resulted in enhanced vasodilatory capacity. Combination treatment with the FOXO1 inhibitor and TIC10 resulted in reduced vascular function compared to control. Immunohistochemical analysis indicated a 3-fold increase in death receptor 5 (DR5) expression in the TIC10-treated blood vessels but the addition of the FOXO1 inhibitor downregulated DR5 expression. The expression of DR4 receptor was not significantly increased in the presence of TIC10; however, addition of the FOXO1 inhibitor downregulated expression. TIC10 has the capacity to improve the function of healthy vessels when stimulated with the vasodilator Ach. This highlights its therapeutic potential not only in cancer treatment without cardiovascular side effects, but also as a possible drug to treat established CVD.
650    _2
$a zvířata $7 D000818
650    12
$a protein FOXO3 $7 D000071316
650    _2
$a lidé $7 D006801
650    12
$a imidazoly $7 D007093
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a fosfatidylinositol-3-kinasy $7 D019869
650    _2
$a králíci $7 D011817
650    _2
$a protein TRAIL $7 D053221
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gadanec, Laura K $u Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia
700    1_
$a Qaradakhi, Tawar $u Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia
700    1_
$a Gammune, Thushira Malindra $u Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia
700    1_
$a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Caprnda, Martin $u 1st Department of Internal Medicine, Faculty of Medicine and University Hospital, Bratislava, Slovakia
700    1_
$a Fedotova, Julia $u Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russian Federation $u International Research Centre "Biotechnologies of the Third Millennium", ITMO University, St. Petersburg, Russian Federation $u Laboratory of Neuroendocrinology, I.P. Pavlov Institute of Physiology, Academy of Sciences, St. Petersburg, Russian Federation
700    1_
$a Radonak, Jozef $u 1st Department of Surgery, Faculty of Medicine, Pavol Jozef Safarik University and University Hospital, Kosice, Slovak Republic
700    1_
$a Kruzliak, Peter $u 2nd Department of Surgery, Faculty of Medicine, Masaryk University and St. Anne´s University Hospital, Brno, Czech Republic
700    1_
$a Zulli, Anthony $u Institute for Health and Sport, Victoria University, Melbourne, Victoria, Australia
773    0_
$w MED00007158 $t Clinical and experimental pharmacology & physiology $x 1440-1681 $g Roč. 47, č. 11 (2020), s. 1816-1823
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32652671 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127144938 $b ABA008
999    __
$a ok $b bmc $g 1752109 $s 1155962
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 47 $c 11 $d 1816-1823 $e 20200803 $i 1440-1681 $m Clinical and experimental pharmacology & physiology $n Clin Exp Pharmacol Physiol $x MED00007158
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

    Možnosti archivace